These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 22336254)

  • 1. Outcomes in atrial fibrillation patients on combined warfarin & antiarrhythmic therapy.
    Guérin A; Lin J; Jhaveri M; Wu EQ; Yu AP; Cloutier M; Gauthier G; Alpert JS
    Int J Cardiol; 2013 Jul; 167(2):564-9. PubMed ID: 22336254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incremental cost burden to US healthcare payers of atrial fibrillation/atrial flutter patients with additional risk factors.
    Amin AN; Jhaveri M; Lin J
    Adv Ther; 2011 Oct; 28(10):907-26. PubMed ID: 21971681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective study of total healthcare costs associated with chronic nonvalvular atrial fibrillation and the occurrence of a first transient ischemic attack, stroke or major bleed.
    Boccuzzi SJ; Martin J; Stephenson J; Kreilick C; Fernandes J; Beaulieu J; Hauch O; Kim J
    Curr Med Res Opin; 2009 Dec; 25(12):2853-64. PubMed ID: 19916729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-year treatment persistence and potential adverse events among patients with atrial fibrillation treated with amiodarone or sotalol: a retrospective claims database analysis.
    Kim MH; Smith PJ; Jhaveri M; Lin J; Klingman D
    Clin Ther; 2011 Nov; 33(11):1668-1681.e1. PubMed ID: 22108302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.
    Agarwal S; Bennett D; Smith DJ
    Am J Cardiovasc Drugs; 2010; 10(1):37-48. PubMed ID: 20104933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns and predictors of discontinuation of rhythm-control drug therapy in patients with newly diagnosed atrial fibrillation.
    Kim MH; Klingman D; Lin J; Battleman DS
    Pharmacotherapy; 2009 Dec; 29(12):1417-26. PubMed ID: 19947801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resource use and cost implications of switching among warfarin formulations in atrial fibrillation patients.
    Kwong WJ; Kamat S; Fang C
    Ann Pharmacother; 2012 Dec; 46(12):1609-16. PubMed ID: 23150608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of dronedarone treatment on healthcare resource utilization in patients with atrial fibrillation/flutter.
    Kim MH; Lin J; Jhaveri M; Koren A
    Adv Ther; 2014 Mar; 31(3):318-32. PubMed ID: 24595638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.
    DiMarco JP; Flaker G; Waldo AL; Corley SD; Greene HL; Safford RE; Rosenfeld LE; Mitrani G; Nemeth M;
    Am Heart J; 2005 Apr; 149(4):650-6. PubMed ID: 15990748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
    J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial.
    Piccini JP; Stevens SR; Lokhnygina Y; Patel MR; Halperin JL; Singer DE; Hankey GJ; Hacke W; Becker RC; Nessel CC; Mahaffey KW; Fox KA; Califf RM; Breithardt G;
    J Am Coll Cardiol; 2013 May; 61(19):1998-2006. PubMed ID: 23500298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective.
    Sorensen SV; Kansal AR; Connolly S; Peng S; Linnehan J; Bradley-Kennedy C; Plumb JM
    Thromb Haemost; 2011 May; 105(5):908-19. PubMed ID: 21431243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study.
    Larsen TB; Rasmussen LH; Skjøth F; Due KM; Callréus T; Rosenzweig M; Lip GY
    J Am Coll Cardiol; 2013 Jun; 61(22):2264-73. PubMed ID: 23562920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of hemorrhage and treatment costs associated with warfarin drug interactions in patients with atrial fibrillation.
    Suh DC; Nelson WW; Choi JC; Choi I
    Clin Ther; 2012 Jul; 34(7):1569-82. PubMed ID: 22717419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of new drugs for management of atrial fibrillation.
    Hollands JM; Gowan M; Riney JN; Deal EN; Kates AM
    Ann Pharmacother; 2012 Dec; 46(12):1656-70. PubMed ID: 23249869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study.
    Jacobs LG; Billett HH; Freeman K; Dinglas C; Jumaquio L
    Am J Geriatr Pharmacother; 2009 Jun; 7(3):159-66. PubMed ID: 19616184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.
    Mahaffey KW; Wojdyla D; Hankey GJ; White HD; Nessel CC; Piccini JP; Patel MR; Berkowitz SD; Becker RC; Halperin JL; Singer DE; Califf RM; Fox KA; Breithardt G; Hacke W
    Ann Intern Med; 2013 Jun; 158(12):861-8. PubMed ID: 23778903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemorrhagic and thrombotic events associated with generic substitution of warfarin in patients with atrial fibrillation: a retrospective analysis.
    Ghate SR; Biskupiak JE; Ye X; Hagan M; Kwong WJ; Fox ES; Brixner DI
    Ann Pharmacother; 2011 Jun; 45(6):701-12. PubMed ID: 21666081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of patients with non-valvular atrial fibrillation using dabigatran or warfarin in the US.
    Schoof N; Schnee J; Schneider G; Gawlik M; Zint K; Clemens A; Bartels DB
    Curr Med Res Opin; 2014 May; 30(5):795-804. PubMed ID: 24392958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.
    Garcia DA; Wallentin L; Lopes RD; Thomas L; Alexander JH; Hylek EM; Ansell J; Hanna M; Lanas F; Flaker G; Commerford P; Xavier D; Vinereanu D; Yang H; Granger CB
    Am Heart J; 2013 Sep; 166(3):549-58. PubMed ID: 24016506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.